IPP-204106 is under clinical development by Immupharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect IPP-204106’s likelihood of approval (LoA) and phase transition for Metastatic Breast Cancer took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their IPP-204106 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

IPP-204106 overview

IPP-204106 is under development for the treatment of advanced solid tumors including metastatic breast cancer, metastatic lung cancer, pancreatic cancer, age-related macular degeneration, metastatic bladder cancer. The drug candidate is administered by the intravenous route. IPP-204106 has a dual mechanism of action, acts by targeting nucleolin/nucleophosmin. It is developed based on the peptide to drug converting technology. The drug candidate was also under development for the treatment of colon cancer, leukemias, melanoma, prostate cancer, and glioblastoma multiforme.

Immupharma overview

Immupharma biopharmaceutical company that focuses on discovery and development of peptide-based therapeutics for the treatment of serious medical conditions with unmet medical need. Immupharma develops drugs for the treatment of lupus, cancer, highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection. The company’s product pipeline comprises Lupuzor, for the treatment of Lupus; BioCIN, for treatment of methicillin-resistant Staphylococcus aureus; BioGlucagon for treatment of diabetes and P140, a drug developed for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. It has operations in France and Switzerland. Immupharma is headquartered in London, Greater London, the UK.

Quick View IPP-204106 LOA Data

Report Segments
  • Innovator
Drug Name
  • IPP-204106
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
  • Ophthalmology
Key Developers
  • Sponsor Company: Immupharma
  • Originator: Centre National de la Recherche Scientifique
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.